Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.29)
# 432
Out of 4,981 analysts
239
Total ratings
42.53%
Success rate
21.03%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Reiterates: Overweight | $105 | $29.54 | +255.45% | 20 | Sep 5, 2025 | |
| PTCT PTC Therapeutics | Reiterates: Overweight | $118 | $59.73 | +97.56% | 21 | Sep 3, 2025 | |
| MNPR Monopar Therapeutics | Reiterates: Overweight | $74 | $53.59 | +38.09% | 2 | Aug 27, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Overweight | $42 → $46 | $44.45 | +3.49% | 3 | Aug 6, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $23 → $32 | $37.60 | -14.89% | 8 | Aug 6, 2025 | |
| EPRX Eupraxia Pharmaceuticals | Initiates: Overweight | $11 | $5.27 | +108.73% | 1 | Jul 24, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Overweight | $25 → $29 | $7.39 | +292.42% | 3 | Jul 10, 2025 | |
| SLDB Solid Biosciences | Assumes: Overweight | $16 | $5.67 | +182.19% | 1 | May 22, 2025 | |
| FULC Fulcrum Therapeutics | Upgrades: Overweight | $10 | $7.09 | +41.04% | 4 | May 15, 2025 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $30 | $6.25 | +380.00% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $163 → $81 | $17.52 | +362.33% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $3.01 | +132.95% | 16 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $67 → $123 | $51.99 | +136.58% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $3.06 | +2,841.18% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $1.78 | +294.37% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $99 → $132 | $58.93 | +123.99% | 8 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $15.52 | +61.08% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $24.66 | +171.70% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $7.75 | +171.14% | 7 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $29 | $7.94 | +265.24% | 13 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $5.16 | +229.78% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $2.83 | +182.69% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $58 | $14.90 | +289.26% | 9 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $2.43 | +353.61% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $5.86 | +207.43% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $4.10 | +241.46% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.50 | +769.57% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.63 | +1,192.31% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.31 | +358.02% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $1.05 | +1,813.88% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $3.81 | +503.67% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $1.54 | +58,341.56% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $2.81 | +14,160.25% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $0.90 | +9,292.78% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $6.96 | +2,488.07% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $2.80 | +6,320.55% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $1.16 | +852.38% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $0.94 | +6,255.93% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.24 | +7,158.06% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $1.48 | +170,170.27% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $160 | $0.48 | +33,261.13% | 1 | Jan 9, 2020 |
Ultragenyx Pharmaceutical
Sep 5, 2025
Reiterates: Overweight
Price Target: $105
Current: $29.54
Upside: +255.45%
PTC Therapeutics
Sep 3, 2025
Reiterates: Overweight
Price Target: $118
Current: $59.73
Upside: +97.56%
Monopar Therapeutics
Aug 27, 2025
Reiterates: Overweight
Price Target: $74
Current: $53.59
Upside: +38.09%
Supernus Pharmaceuticals
Aug 6, 2025
Maintains: Overweight
Price Target: $42 → $46
Current: $44.45
Upside: +3.49%
Rigel Pharmaceuticals
Aug 6, 2025
Maintains: Neutral
Price Target: $23 → $32
Current: $37.60
Upside: -14.89%
Eupraxia Pharmaceuticals
Jul 24, 2025
Initiates: Overweight
Price Target: $11
Current: $5.27
Upside: +108.73%
Zevra Therapeutics
Jul 10, 2025
Maintains: Overweight
Price Target: $25 → $29
Current: $7.39
Upside: +292.42%
Solid Biosciences
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $5.67
Upside: +182.19%
Fulcrum Therapeutics
May 15, 2025
Upgrades: Overweight
Price Target: $10
Current: $7.09
Upside: +41.04%
Capricor Therapeutics
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $6.25
Upside: +380.00%
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $17.52
Upside: +362.33%
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $3.01
Upside: +132.95%
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $51.99
Upside: +136.58%
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $3.06
Upside: +2,841.18%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $1.78
Upside: +294.37%
Mar 18, 2025
Maintains: Overweight
Price Target: $99 → $132
Current: $58.93
Upside: +123.99%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $15.52
Upside: +61.08%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $24.66
Upside: +171.70%
Jan 15, 2025
Reiterates: Overweight
Price Target: $21
Current: $7.75
Upside: +171.14%
Jan 2, 2025
Reiterates: Overweight
Price Target: $29
Current: $7.94
Upside: +265.24%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $5.16
Upside: +229.78%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $2.83
Upside: +182.69%
Dec 10, 2024
Maintains: Overweight
Price Target: $28 → $58
Current: $14.90
Upside: +289.26%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.43
Upside: +353.61%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $5.86
Upside: +207.43%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $4.10
Upside: +241.46%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $1.50
Upside: +769.57%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.63
Upside: +1,192.31%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.31
Upside: +358.02%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $1.05
Upside: +1,813.88%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $3.81
Upside: +503.67%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $1.54
Upside: +58,341.56%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $2.81
Upside: +14,160.25%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $0.90
Upside: +9,292.78%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $6.96
Upside: +2,488.07%
May 26, 2021
Initiates: Overweight
Price Target: $180
Current: $2.80
Upside: +6,320.55%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $1.16
Upside: +852.38%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $0.94
Upside: +6,255.93%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.24
Upside: +7,158.06%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $1.48
Upside: +170,170.27%
Jan 9, 2020
Initiates: Overweight
Price Target: $160
Current: $0.48
Upside: +33,261.13%